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A B S T R A C T
In Huntington's disease (HD), the presence of neurodegeneration in brain regions other than the striatum has
been recently gaining attention. The amygdala is one such area, which has been investigated in only eight
structural magnetic resonance imaging studies to date, but with inconsistent ﬁndings. This is the largest MRI
study to date examining manually traced amygdala volumes in HD participants and the relationship of amygdala
volumes to clinical measures of HD. Our study included 35 healthy control participants, and groups of 35 pre-
symptomatic, and 36 symptomatic HD participants. When comparing the pre-symptomatic and symptomatic HD
groups together against the control group, amygdala volumes were signiﬁcantly lower in HD than controls and in
symptomatic HD than pre-symptomatic HD. When examining relationships between amygdala volumes and
clinical measures of HD, signiﬁcantly smaller amygdala volumes were associated with worse motor and cog-
nitive signs. For pre-symptomatic HD participants who were close to disease onset, smaller amygdala volumes
were also associated with higher levels of anxiety symptoms. These ﬁndings suggest that the amygdala is aﬀected
in pre-symptomatic and symptomatic HD, and that the amygdala is related to the clinical proﬁle of HD before
onset of motor symptoms.
1. Introduction
Huntington's disease (HD) is an autosomal dominant neurodegen-
erative disorder that causes motor, cognitive, and psychiatric symptoms
(Bates et al., 2015; Papoutsi et al., 2014). Historically, neuropatholo-
gical and neuroimaging studies in HD focussed on the striatum, the
brain area most severely aﬀected across the course of the disease
(Walker, 2007; Georgiou-Karistianis et al., 2013). Atrophy in brain re-
gions outside of the striatum, and early in the course of HD, however, is
of considerable interest (cortical areas: Tabrizi et al., 2009; Gray et al.,
2013; thalamus: Jernigan et al., 1991; hippocampus: Brito et al., 2014).
The amygdala, a subcortical almond-shaped structure located deep in
the medial temporal lobe, has been gaining interest because of its close
functional connectivity with the striatum, the brain region most se-
verely aﬀected across the course of HD (Roy et al., 2009). Further, the
amygdala has been ascribed to key cognitive and psychiatric symptoms
that occur in the course of HD, including aberrant emotion recognition,
regulation, and social behaviour, depression, and anxiety (Adolphs
et al., 1994; Adolphs et al., 1997; Fine and Blair, 2000; Phelps and
Ledoux, 2005). Nevertheless, only few studies have investigated the
involvement of the amygdala in HD, and so far, results have been in-
consistent.
The ﬁrst study to demonstrate amygdala abnormalities in HD
compared voxel-based morphometry and manual segmentation for
measuring subcortical volumes (Douaud et al., 2006). Although the
research focus was not on the amygdala, the voxel-based morphometry
analysis indicated smaller amygdala volumes in symptomatic HD par-
ticipants when compared to controls (Douaud et al., 2006). A later
study showed similar results in pre-symptomatic HD (Kipps et al.,
2007). In fMRI studies, pre-symptomatic and symptomatic HD partici-
pants have shown less activity in the amygdala and less connectivity
between the amygdala and the fusiform face area than controls (Mason
et al., 2015; Van Den Stock et al., 2015; Klöppel et al., 2010). In ad-
dition, a recent meta-analysis that investigated current evidence on
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brain atrophy in HD has demonstrated that smaller amygdala volumes
are generally shown in pre-symptomatic HD compared to controls
(Dogan et al., 2013). Together, these studies indicate that the amygdala
is aﬀected at pre-symptomatic and symptomatic stages of HD. Of note
are also ﬁndings of amygdala atrophy in Parkinson's disease (De La
Monte et al., 1989; Cordato et al., 2000; Harding et al., 2002), often
used as a comparison to HD because of the mutual yet selective in-
volvement of the basal ganglia.
In contrast to evidence that the amygdala is aﬀected in HD, other
studies have not revealed evidence for amygdala degeneration in HD.
For example, using the transgenic rat model of HD, no diﬀerences in
amygdala volumes were found between wild-type rats and HD rats
(Faure et al., 2011). Similarly, in a volumetric human study, the
amygdala was the only structure of seven brain areas (including the
basal ganglia, hippocampus, and thalamus) that was not smaller in pre-
symptomatic and symptomatic HD compared to controls (Van Den
Bogaard et al., 2011). These inconsistent ﬁndings may be a result of
underpowered studies due to small sample sizes, and the use of auto-
mated segmentation methods, which are insensitive to subtle and spa-
tially complex grey matter diﬀerences between groups (Davatzikos,
2004). Alongside inconsistent ﬁndings, no HD study has yet compared
amygdala volumes between participants with pre-symptomatic HD and
symptomatic HD, or related amygdala volumes to clinical symptoms.
In this paper, we report a cross-sectional analysis of amygdala vo-
lumetry in pre-symptomatic and symptomatic HD using data from the
Australian-based IMAGE-HD study (Dominguez et al., 2013; Georgiou-
Karistianis et al., 2013; Dominguez et al., 2016). In addition, we report
on relationships between amygdala volumes and clinical and patholo-
gical measures, including motor and psychiatric symptoms, disease
burden, and caudate and putamen volumes. Based on previous work
suggesting that amygdala atrophy may occur in HD, we hypothesised
that amygdala volumes would be smaller in participants with the HD
gene overall (both pre-symptomatic and symptomatic), and relatively
smaller for symptomatic HD than pre-symptomatic HD participants. In
light of previous evidence of associations between atrophy in the
striatum and sensorimotor cortex and clinical measures in HD (Dogan
et al., 2013; Tabrizi et al., 2011), we hypothesised that smaller amyg-
dala volumes would be associated with higher levels of motor, cogni-
tive, and psychiatric symptoms, and worse disease burden scores and
smaller caudate and putamen volumes.
2. Material and methods
2.1. Participants
The sample consisted of 106 participants, of whom 59 were females:
35 pre-symptomatic HD, 36 symptomatic HD, and 35 healthy controls
(Table 1). The age of all participants ranged from 23 to 72 years old
(M=45.44, SD=12.17), but because of the natural course of HD, the
symptomatic HD group was older than the pre-symptomatic HD and
control groups (F(2,103)= 8.94, p < .001). Gender did not diﬀer
signiﬁcantly between groups (F(2,103)= 2.31, p= .10). The study was
approved by Monash University's Human Research Ethics Committee
and Melbourne Health Human Research Ethics Committee, and in-
formed written consent was obtained from each participant prior to
testing.
2.2. Amygdala volumetry
2.2.1. Image acquisition and pre-processing
High resolution MRI data from the IMAGE-HD study was acquired
using a Siemens 3 Telsa scanner with a 32-channel head coil at the
Murdoch Children's Research Institute (Royal Children's Hospital,
Victoria, Australia). Acquisition parameters for the T1-weighted images
consisted of 192 slices, voxel size 0.9, 0.8mm×0.8mm, 9° ﬂip angle.
FOV was 320× 320, inversion time 900ms, TE 2.59ms, RT 1900ms.
To allow for comparison of regional grey matter volumes, the raw MRI
images were re-oriented, and re-sized using the Freesurfer imaging
analysis suite (Martinos Center for Biomedical Imaging, Harvard-MIT,
Boston, USA). Participant's images were de-identiﬁed prior to volu-
metric analysis to minimise any biases.
2.2.2. Volumetric analysis
The right and left amygdala was manually delineated on coronal
slices using the software ANALYZE 12.0 (Mayo Clinic, Rochester, NY),
and following a well validated protocol (Velakoulis et al., 2006). Seg-
mentation began at the caudal end of the amygdala and proceeded,
slice by slice, rostrally until the amygdala was no longer visible. To
ensure consistency of manual segmentation across each brain, each
slice was displayed with the segmentations from the previous slice,
which was then edited to reﬂect the shift in the amygdala boundary for
that slice.
The total amygdala volume was calculated by summing the volume
for the voxels included across all slices. To account for individual dif-
ferences in head size, right and left amygdala volumes were normalised
by regressing out total intracranial volume, following the residual
Table 1
Participants' demographic information.
Pre-symptomatic HD Symptomatic HD Controls
n 35 36 35
Males (%) 14 (40%) 21 (58%) 12 (34%)
Females (%) 21 (60%) 15 (42%) 23 (66%)
Mood medication (%) 6 (17%) 16 (44%) 0
Age (mean ± SD)
(Range)
41.59 ± 10.00
(23.93–65.29)
51.91 ± 9.36
(38.99–70.84)
42.63 ± 14.14
(24.38–72.98)
HADS Anxiety (mean ± SD)
(Range)
6.83 ± 3.37
(1–14)
5.47 ± 3.44
(0–14)
4.97 ± 2.81
(0−11)
HADS Depression (mean ± SD)
(Range)
2.74 ± 2.97
(0−12)
2.89 ± 2.38
(0–8)
2.23 ± 2.10
(0–8)
UHDRS TMS (mean ± SD)
(Range)
0.94 ± 1.24
(0–4)
19.47 ± 12.42
(6–60)
–
–
CAG repeats (mean ± SD)
(Range)
42.31 ± 1.97
(39–46)
43.17 ± 2.48
(40–50)
–
–
DBS (mean ± SD)
(Range)
269.70 ± 53.41
(131.64–369.60)
379.70 ± 70.02
(258.14–556.97)
-
-
Abbreviations. UHDRS TMS=Uniﬁed Huntington's Disease Rating Scale total motor score. HADS=Hospital Anxiety and Depression Scale. DBS=disease burden score.
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method described by Free et al. (1995).
For intra-rater and inter-rater reliability for amygdala, tracing was
assessed using intra-class correlation coeﬃcient (ICC). Intra-rater re-
liability was determined for the right (ICC= 0.97) and left amygdala
(ICC=0.96) using ten randomly selected MRIs delineated by the same
tracer (LA) on two occasions, at the beginning of the tracing period and
at the end, three months later, to map any potential drift in reliability
over time (ICCs were 0.89 for the right and 0.84 for the left amygdala).
To establish inter-rater reliability, a diﬀerent rater (YG-J) measured
amygdala volumes on the same set of ten scans ICCs, and inter-rater
reliabilities were 0.88 and 0.80 for right and left amygdala, respec-
tively.
2.3. Clinical measures and measures of disease pathology
We measured psychiatric symptoms with the Hospital Anxiety and
Depression Scale (HADS; Zigmond and Snaith, 1983), and motor
symptoms with the Uniﬁed Huntington's Disease Rating Scale (UHDRS;
Huntington Study Group, 1996) total motor scores (TMS). Cognitive
symptoms were measured using the Symbol Digit Modalities Test
(SDMT; Smith, 1982), Stroop Word Test (Stroop, 1935), and the Uni-
versity of Pennsylvania Smell Identiﬁcation Test (UPSIT; Doty et al.,
1984).
The HADS is a self-administered questionnaire that screens for le-
vels of depression and anxiety, and consists of 7 items scored on a scale
of 0–3. Scores above 7 on either subscale indicate signiﬁcant levels of
depression or anxiety. Our three groups showed similar levels of de-
pressive symptoms, and the pre-symptomatic HD group indicated
slightly higher anxiety symptoms than controls (Georgiou-Karistianis
et al., 2013).
The SDMT is a brief measure of visuomotor speed and attention, and
involves matching symbols to their corresponding numbers in 90 s. The
SDMT is scored according to the number of correct answers. Next, the
Stroop Word Test is a measure of processing speed, which involves
naming the colour of written colour names as quickly as possible. The
Stroop Word Test is scored according to number of correct words. Next,
the UPSIT is a measure of odour recognition, which involves categor-
ising diﬀerent odours and is scored according to normative data. In our
sample, symptomatic HD participants performed worse on the SDMT,
Stroop Word Test, and UPSIT than pre-symptomatic and control parti-
cipants. In addition, pre-symptomatic HD participants performed worse
than controls on the SDMT, although both groups performed similarly
on the UPSIT and Stroop Word Test (Georgiou-Karistianis et al., 2013).
The motor section of the UHDRS is an assessment of motor signs of
HD by a trained examiner, and consists of 31 items scored on a range
from 0 to 4, and summed for the TMS. A TMS over 5 demonstrates
substantial motor signs. In our sample, the symptomatic HD group
showed greater motor signs than the pre-symptomatic HD group
(Georgiou-Karistianis et al., 2013).
We used previously acquired data from the IMAGE-HD study for
measures of disease pathology, which included disease burden scores
(DBS) and volumetry of the caudate nucleus and putamen (Georgiou-
Karistianis et al., 2013) to examine the relationship between disease
pathology and amygdala volumes. The DBS is an estimate of the pa-
thological burden of HD, and is calculated based on the participant age
and cytosine-guanine-adenine (CAG) repeat length (age× [CAG repeat
number− 35.5]) (Dominguez et al., 2013; Penney et al., 1997). As
expected, the symptomatic HD group showed greater disease burden
than the pre-symptomatic HD group (F(1,69)= 55.17, p < .001). Es-
timated years to diagnosis for the pre-symptomatic HD participants was
calculated using the following formula: years to onset= (21.54+EXP
(9.556− 0.146×CAG repeat number)− age (Langbehn et al., 2004).
Volumes of the caudate nucleus and putamen were not available for 3
of our pre-symptomatic and 6 of our symptomatic participants, and
therefore these 9 HD participants were removed from this analysis. In
the resulting sample, the symptomatic HD group showed smaller
caudate and putamen volumes than the pre-symptomatic HD group
(Wilk's Lambda=0.80, F(4,57)= 3.59, p= .011), as previously shown
by Georgiou-Karistianis et al. (2013).
2.4. Statistical analyses
Total amygdala volumes were compared between the three groups
(pre-symptomatic HD, symptomatic HD, and controls) using an analysis
of variance (ANOVA) with two planned contrasts. The ﬁrst contrast
examined diﬀerences in total amygdala volumes between controls and
both HD groups (pre-symptomatic and symptomatic HD), and the
second contrast investigated diﬀerences between the pre-symptomatic
and symptomatic HD groups. The association between amygdala vo-
lumes and UHDRS TMS, HADS Anxiety and Depression scores, SDMT,
Stroop Word Test, UPSIT, DBS, and caudate and putamen volumes were
examined in bivariate linear regression analyses. We used SPSS version
23 (SPSS Inc., Chicago, IL, USA) for all statistical analyses.
3. Results
We found that amygdala volumes were lower in both symptomatic
HD and pre-symptomatic HD compared to controls, and in symptomatic
HD compared to pre-symptomatic HD. Within all groups, left and right
amygdalae were non-signiﬁcantly diﬀerent [control group: F
(1,68)= 0.10, p= .75, pre-symptomatic HD: F(1,68)= 0.033, p= .86,
symptomatic HD: F(1,70)= 0.052, p= .82]. The eﬀect of group
membership on total amygdala volumes (as well as right and left se-
parately) was signiﬁcant (F(2,103)= 27.64, p < .001, with a large
eﬀect size, ηp2= 0.40; Table 2, Fig. 1) with both pre-symptomatic and
symptomatic HD participants having smaller total amygdala volumes
than controls, t(103)= 7.34, p < .001 (large eﬀect size, ηp2= 0.34).
Further, symptomatic HD participants showed smaller total amygdala
volumes than pre-symptomatic HD, t(103)= 2.56, p= .012, with a
small eﬀect size, ηp2= 0.060.
Symptomatic HD participants are naturally older than those with
pre-symptomatic HD. Moreover, the controls were matched by age to
the pre-symptomatic HD participants, and thus in our sample age and
group are confounded. To address this confound, in a separate set of
analyses, we excluded the four youngest control participants (n=31
remaining), the ﬁve youngest pre-symptomatic HD participants (n=30
remaining), and the ﬁve oldest symptomatic HD participants (n=32
Table 2
Amygdala volumetry for pre-symptomatic HD, symptomatic HD, and healthy controls
within the total sample and age-matched sample.
Hemisphere Mean (SD) 95% CI
Total sample
Pre-symptomatic HD R 979.90 (129.59) [927.36, 1032.43]
L 974.27 (129.01) [924.75, 1032.79]
Total 1954.17 (235.65) [1860.58, 2047.76]
Symptomatic HD R 895.83 (144.58) [844.03, 947.64]
L 888.41 (132.61) [839.78, 937.24]
Total 1784.24 (256.58) [1691.97, 1876.52]
Controls R 1128.21 (189.98) [1075.67, 1180.75]
L 1142.17 (177.09) [1092.65, 1191.69]
Total 2270.38 (335.85) [2176.80, 2363.97]
Age-matched sample
Pre-symptomatic HD R 986.09 (124.73) [934.06, 1038.12]
L 970.00 (121.35) [919.92, 1020.08]
Total 1956.09 (228.56) [1863.20, 2048.99]
Symptomatic HD R 913.78 (139.31) [863.40, 964.16]
L 894.61 (131.42) [846.12, 943.10]
Total 1808.39 (252.28) [1718.45, 1898.33]
Controls R 1110.83 (163.22) [1059.65, 1162.02]
L 1138.58 (158.46) [1089.31, 1187.85]
Total 2249.41 (283.72) [2158.03, 2340.79]
Abbreviations. R= right amygdala. L= left amygdala. Total= right+ left amygdala.
CI= conﬁdence interval.
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remaining; Table 2). Although this sample yielded relatively less power
than the analyses with the full sample, analyses of this age-matched
subset indicated that the group eﬀect remained statistically signiﬁcant
for the amygdala volumes (F(2,90)= 24.09, p < .001, large eﬀect,
η2= 0.34). The pattern of diﬀerences between the groups in total
amygdala volumes was unchanged with smaller volumes in pre-symp-
tomatic HD and in symptomatic HD than controls, (t(90)= 6.83,
p < .001, large eﬀect size, η2= 0.34), and smaller volumes in symp-
tomatic HD than pre-symptomatic HD (t(90)= 2.27, p= .026, small
eﬀect size, η2= 0.054). By combining the unmatched and age-matched
approaches, we suggest that the diﬀerences in amygdala volumes be-
tween the three groups were not attributable to age.
We found that smaller total amygdala volumes were associated with
worse motor signs (UHDRS TMS scores) and poorer cognitive perfor-
mances (SDMT and Stroop Word Test scores) in pre-symptomatic and
symptomatic HD participants (Table 3; Fig. 2). Amygdala volumes were
not associated with odour recognition (UPSIT scores), or psychiatric
symptoms (HADS scores), although both results suggested statistical
trends. Finally, disease burden (i.e. DBS), and caudate and putamen
volumes were also not signiﬁcantly associated with amygdala volumes.
Psychiatric symptoms are thought to occur in HD before clinical
diagnosis, and in order to asses if the amygdala is related to these
symptoms we analysed the pre-symptomatic cohort further. We divided
the pre-symptomatic HD group into far and close to estimated disease
onset, using a median of 9.66 years to diagnosis. We found that in the
close to onset group, lower total amygdala volumes were associated
with greater anxiety symptoms and worse motor signs (Table 4, Fig. 3).
In contrast, in the far from onset group of pre-symptomatic HD parti-
cipants, amygdala volumes were not associated with any clinical mea-
sures. Amygdala volumes were not associated with odour recognition or
cognitive performance in either group.
4. Discussion
In this study, we showed cross-sectional evidence that volume loss
in the amygdala begins in HD before clinical diagnosis and occurs to a
greater extent after diagnosis, and that this volume loss is related to
motor, cognitive, and psychiatric signs. To the best of our knowledge,
Fig. 1. Mean total amygdala volumes for control, pre-
symptomatic HD, and symptomatic HD groups. Pre-symp-
tomatic HD and symptomatic HD participants had sig-
niﬁcantly lower amygdala volumes than control partici-
pants. Symptomatic HD participants had signiﬁcantly lower
amygdala volumes than pre-symptomatic HD participants.
Two asterisks indicate a signiﬁcance of p < .001 and one
asterisk indicates a signiﬁcance of p < .05.
Table 3
Inferential statistics for the relationship between amygdala volumes and clinical measures
and measures of disease pathology in HD participants.
B SE t p η2 95% CI
UHDRS TMS −7.47 2.26 −3.31 .001⁎⁎ 0.14 [−11.98,
−2.97]
SDMT 5.70 2.31 2.47 .016⁎⁎ 0.081 [1.09, 10.32]
Stroop Word Test 3.08 1.36 2.27 .026⁎⁎ 0.070 [0.38, 5.78]
UPSIT 4.75 4.43 1.07 .29 0.016 [−4.09, 13.58]
HADS Anxiety 6.99 11.06 0.63 .53 0.006 [−15.09,
29.06]
HADS Depression −11.35 14.30 −0.79 .43 0.009 [−39.87,
17.18]
Disease burden
score
−0.70 0.37 −1.92 .059 0.051 [−1.43, 0.029]
Right caudate −19.41 16.72 −1.16 .25 0.023 [−52.89,
14.08]
Left caudate 25.37 16.64 1.53 .13 0.039 [−7.95, 58.70]
Right putamen −14.35 19.06 −0.75 .46 0.010 [−52.52,
23.83]
Left putamen 3.77 18.21 0.21 .84 0.001 [−32.69,
40.24]
Abbreviations. B= unstandardised regression coeﬃcient. SE= standard error.
CI= conﬁdence interval. UHDRS TMS=Uniﬁed Huntington's Disease Rating Scale Total
Motor Score. SDMT=Symbol Digit Modalities Test. UPSIT=University of Pennsylvania
Smell Identiﬁcation Test. HADS=Hospital Anxiety and Depression Scale.
⁎⁎ p < .05.
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this is the ﬁrst study in HD to directly compare amygdala volumetry
between pre-symptomatic and symptomatic participants and demon-
strate an association between amygdala atrophy and clinical sympto-
matology across the diﬀerent disease stages. Our results reinforce the
importance of extra-striatal structures in the clinical manifestation of
HD.
A direct comparison of brain volume loss between pre-symptomatic
and symptomatic HD is complex because of the expected diﬀerences in
age and disease status. Nonetheless, our sub-analysis of an age-matched
sample yielded the same pattern of results as the non-age matched
groupings, suggesting that the ﬁndings of amygdala volume decrements
in early HD cannot be explained by the older age of the group. Our
ﬁndings clearly support the idea that HD exerts a detrimental eﬀect on
brain areas outside the striatum (cortical areas: Tabrizi et al., 2009;
thalamus: Jernigan et al., 1991; and hippocampus: Brito et al., 2014),
including the amygdala (Dogan et al., 2013; Douaud et al., 2006; Kipps
et al., 2007), which begins early in the disease.
Our measures of amygdala volumes were not statistically associated
with measures of disease reported in the IMAGE-HD study, including
disease burden scores, and the size of the caudate nucleus and putamen
(Dominguez et al., 2013; Georgiou-Karistianis et al., 2013; Dominguez
et al., 2016). A lack of an association between amygdala volumes and
measures of disease is somewhat surprising considering that striatal
degeneration is thought to predict or strongly associate with many
clinical and neurological signs of HD, including with deﬁcits related to
amygdala function. As an example is a recent functional MRI study that
found an association between reduced anger-selective activation in the
amygdala and smaller dorsal striatum volumes in pre-symptomatic HD
(Van Den Stock et al., 2015). The lack of association observed in our
study may be explained by the diﬀerent rates of volume loss in amyg-
dala versus striatal structures during the course of HD. The amygdala
was approximately 7.6% smaller in symptomatic HD than pre-symp-
tomatic HD, while the caudate and putamen were approximately 17.7%
and 10.3% smaller in symptomatic HD than pre-symptomatic HD (see
Fig. 4), as shown in the IMAGE-HD study (Dominguez et al., 2013;
Georgiou-Karistianis et al., 2013; Dominguez et al., 2016). Further-
more, the diﬀerent rates of volumes loss in the amygdala and striatal
structures may also explain the lack of an association between amyg-
dala volumes and disease burden scores, because disease burden scores
are strongly linked to striatal pathology in HD (Penney et al., 1997).
In contrast, we did observe a relationship between the size of the
amygdala and the degree of motor signs, in which smaller amygdala
volumes were related to greater levels of motor signs. This relationship
was dependent on proximity to disease onset: smaller amygdala vo-
lumes were related to worse motor signs in pre-symptomatic HD par-
ticipants who were estimated to be close to disease onset, but not in
those who were estimated to be far from disease onset. Atrophy in the
striatum (Dominguez et al., 2013) and in primary motor and sensor-
imotor cortices (Dogan et al., 2013) has previously been shown to be
associated with motor signs. IMAGE-HD is the ﬁrst study to demon-
strate an association between atrophy in the amygdala and motor signs.
In addition to the association with motor signs, we found a re-
lationship between amygdala volumes and cognitive signs. In this re-
lationship, smaller amygdala volumes were associated with worse vi-
suomotor skills and slower processing speed, which are the two
cognitive outcomes that demonstrate HD related changes most sensi-
tively (Stout et al., 2012). Previously, other cognitive signs, speciﬁcally
deﬁcits in emotion recognition, were shown to be associated with
amygdala volumetry in HD (Kipps et al., 2007). We also found a trend
for associations with neuropsychiatric signs, with smaller amygdala
volumes being associated with higher levels of anxiety and depressive
symptoms. Assessing our pre-symptomatic HD group further, we found
an association between smaller amygdala volumes and greater anxiety
symptoms in pre-symptomatic HD participants who were nearing esti-
mated disease onset. Previously, research has shown that psychiatric
Fig. 2. UHDRS TMS (A), SDMT Scores (B), and Stroop Word Test (C) scores across total amygdala volumes for pre-symptomatic and symptomatic HD participants. Smaller amygdala
volumes are associated with higher levels of motor signs (p < .05), and worse cognitive performance (p < .05).
Table 4
Inferential statistics for the relationship between amygdala volumes and clinical measures
in pre-symptomatic HD participants divided into close and far from disease onset.
B SE t p η2 95% CI
Close to onset
UHDRS TMS −80.60 35.47 −2.27 .041⁎⁎ 0.28 [−157.22,
−3.97]
SDMT 9.39 6.50 1.45 .17 0.13 [−4.55, 23.33]
Stroop Word Test 3.57 3.15 1.13 .28 0.079 [−3.15, 10.92]
UPSIT −13.51 9.35 −1.45 .17 0.13 [−33.57, 6.55]
HADS Anxiety −46.79 21.08 −2.22 .045⁎⁎ 0.28 [−92.33,
−1.25]
HADS Depression 36.72 24.23 1.52 .15 0.15 [−15.61,
89.06]
Far from onset
UHDRS TMS −73.47 69.24 −1.06 .31 0.074 [−221.98,
75.03]
SDMT −5.63 6.75 −0.83 .42 0.044 [−20.02, 8.76]
Stroop Word Test −4.90 3.00 −1.63 .12 0.14 [−11.26, 1.47]
UPSIT 9.22 14.65 0.63 .54 0.026 [−22.01,
40.44]
HADS Anxiety 0.58 21.74 0.027 .98 0.00 [−46.04,
47.20]
HADS Depression −1.78 23.02 −0.077 .94 0.00 [−51.16,
47.60]
Abbreviations. B= unstandardised regression coeﬃcient. SE= standard error.
CI= conﬁdence interval. UHDRS TMS=Uniﬁed Huntington's Disease Rating Scale Total
Motor Score. SDMT=Symbol Digit Modalities Test. UPSIT=University of Pennsylvania
Smell Identiﬁcation Test. HADS=Hospital Anxiety and Depression Scale.
⁎⁎ p < .05.
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symptoms, particularly anxiety symptoms, begin subtly in the pre-
symptomatic phase and continue to peak with worsening motor signs
(Duﬀ et al., 2007). Our ﬁndings extend on the current literature by
showing that the amygdala is related to the increase in anxiety symp-
toms seen in the stage close to clinical diagnosis.
Amygdala volumes were not associated with odour recognition,
despite known associations between the amygdala and olfactory pro-
cessing (Ledoux, 2004; Rosenkranz and Grace, 2002; Schoenbaum
et al., 1999). In our sample, pre-symptomatic and symptomatic HD
participants scored similarly on the UPSIT and within a narrow range,
so we would not have expected to see associations within our dataset
(Georgiou-Karistianis et al., 2013).
5. Conclusions
In conclusion, this study provides ﬁndings that are important to
understanding how abnormalities in extra-striatal structures, in addi-
tion to degeneration in striatal and cortical areas, may contribute to the
manifestation of HD in the years before onset of clinical symptoms and
across the disease. Furthermore, our work highlights the need for the
brain in HD to be considered as a uniﬁed whole, rather than separate
structures and areas targeted individually by HD.
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